Pharmacologic treatment of dimensional anxious depression: A review

Primary Care Companion to the Journal of Clinical Psychiatry

Volumn 16, Issue 3, 2014, Pages

  Ionescu, Dawn F ^a   Niciu, Mark J ^a   Richards, Erica M ^a   Zarate Jr , Carlos A ^a  

^a NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84904254223     PISSN: 15235998     EISSN: 1555211X     Source Type: Journal    
DOI: 10.4088/PCC.13r01621     Document Type: Review

References (52)

1. Fava M, Rush AJ, Alpert JE, et al. Difference in treatment outcome in outpatients with anxious versus nonanxious depression: a STAR*D report. Am J Psychiatry. 2008;165(3):342-351. doi:10.1176/appi.ajp.2007.06111868 PubMed
2. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition. Arlington, VA: American Psychiatric Publishing; 2013.
3. Niciu MJ, Mathews DC, Nugent AC, et al. Developing biomarkers in mood disorders research through the use of rapid-acting antidepressants[published online ahead of print December 18, 2013]. Depress Anxiety. doi:10.1002/da.22224 PubMed
4. Fava M, Alpert JE, Carmin CN, et al. Clinical correlates and symptom patterns of anxious depression among patients with major depressive disorder in STAR*D. Psychol Med. 2004;34(7):1299-1308. doi:10.1017/S0033291704002612 PubMed
5. Domschke K, Deckert J, Arolt V, et al. Anxious versus non-anxious depression: difference in treatment outcome. J Psychopharmacol. 2010;24(4):621-622. doi:10.1177/0269881108097723 PubMed
6. Köhler S, Unger T, Hoffmann S, et al. Acute and long-term treatment outcome in depressed inpatients with versus without anxious features: results of a one-year follow-up study. J Affect Disord. 2013;150(3):1055-1061. doi:10.1016/j.jad.2013.05.043 PubMed
7. Seo HJ, Song HR, Jeong S, et al. Does comorbid subthreshold anxiety predict treatment response in depression? results from a naturalistic cohort study (the CRESCEND study). J Affect Disord. 2014;152-154:352-359. doi:10.1016/j.jad.2013.09.037 PubMed
8. Tollefson GD, Holman SL, Sayler ME, et al. Fluoxetine, placebo, and tricyclic antidepressants in major depression with and without anxious features. J Clin Psychiatry. 1994;55(2):50-59. PubMed
9. Nelson JC. Anxiety does not predict response to duloxetine in major depression: results of a pooled analysis of individual patient data from 11 placebo-controlled trials. Depress Anxiety. 2010;27(1):12-18. doi:10.1002/da.20632 PubMed
10. Altamura AC, Montresor C, Salvadori D, et al. Does comorbid subthreshold anxiety affect clinical presentation and treatment response in depression? a preliminary 12-month naturalistic study. Int J Neuropsychopharmacol. 2004;7(4):481-487. doi:10.1017/S1461145704004626 PubMed
11. Clayton PJ, Grove WM, Coryell W, et al. Follow-up and family study of anxious depression. Am J Psychiatry. 1991;148(11):1512-1517. PubMed
12. Ionescu DF, Niciu MJ, Henter ID, et al. Defining anxious depression: a review of the literature. CNS Spectr. 2013;18(5):252-260. doi:10.1017/S1092852913000114 PubMed
13. Cleary P, Guy W. Factor analysis of Hamilton Depression Scale. Drugs Exp Clin Res. 1977;1:115-120.
14. McClintock SM, Husain MM, Bernstein IH, et al. Assessing anxious features in depressed outpatients. Int J Methods Psychiatr Res. 2011;20(4):e69-e82. doi:10.1002/mpr.353 PubMed
15. Pollack MH. Comorbid anxiety and depression. J Clin Psychiatry. 2005;66(suppl 8):22-29. PubMed
16. Spalletta G, Pasini A, Caltagirone C. Fluoxetine alone in the treatment of first episode anxious-depression: an open clinical trial. J Clin Psychopharmacol. 2002;22(3):263-266. doi:10.1097/00004714-200206000-00006 PubMed
17. Fava M, Rosenbaum JF, Hoog SL, et al. Fluoxetine versus sertraline and paroxetine in major depression: tolerability and efficacy in anxious depression. J Affect Disord. 2000;59(2):119-126. doi:10.1016/S0165-0327(99)00131-7 PubMed
18. Feiger AD, Flament MF, Boyer P, et al. Sertraline versus fluoxetine in the treatment of major depression: a combined analysis of five double-blind comparator studies. Int Clin Psychopharmacol. 2003;18(4):203-210. doi:10.1097/00004850-200307000-00002 PubMed
19. Papakostas GI, Fan H, Tedeschini E. Severe and anxious depression: combining definitions of clinical subtypes to identify patients differentially responsive to selective serotonin reuptake inhibitors. Eur Neuropsychopharmacol. 2012;22(5):347-355. doi:10.1016/j.euroneuro.2011.09.009 PubMed
20. Farabaugh A, Mischoulon D, Fava M, et al. The relationship between early changes in the HAMD-17 anxiety/somatization factor items and treatment outcome among depressed outpatients. Int Clin Psychopharmacol. 2005;20(2):87-91. doi:10.1097/00004850-200503000-00004 PubMed
21. Farabaugh AH, Bitran S, Witte J, et al. Anxious depression and early changes in the HAMD-17 anxiety-somatization factor items and antidepressant treatment outcome. Int Clin Psychopharmacol. 2010;25(4):214-217. doi:10.1097/YIC.0b013e328339fbbd PubMed
22. Papakostas GI, Clain A, Ameral VE, et al. Fluoxetine-clonazepam cotherapy for anxious depression: an exploratory, post-hoc analysis of a randomized, double blind study. Int Clin Psychopharmacol. 2010;25(1):17-21. doi:10.1097/YIC.0b013e32833205a4 PubMed
23. Fava M, Schaefer K, Huang H, et al. A post hoc analysis of the effect of nightly administration of eszopiclone and a selective serotonin reuptake inhibitor in patients with insomnia and anxious depression. J Clin Psychiatry. 2011;72(4):473-479. doi:10.4088/JCP.09m05131gry PubMed
24. Nasso ED, Chiesa A, Serretti A, et al. Clinical and demographic predictors of improvement during duloxetine treatment in patients with major depression: an open-label study. Clin Drug Investig. 2011;31(6):385-405. doi:10.2165/11588800-000000000-00000 PubMed
25. Fava M, Martinez JM, Greist J, et al. The efficacy and tolerability of duloxetine in the treatment of anxious versus nonanxious depression: a post-hoc analysis of an open-label outpatient study. Ann Clin Psychiatry. 2007;19(3):187-195. doi:10.1080/10401230701465178 PubMed
26. Howland RH, Wilson MG, Kornstein SG, et al. Factors predicting reduced antidepressant response: experience with the SNRI duloxetine in patients with major depression. Ann Clin Psychiatry. 2008;20(4):209-218. doi:10.1080/10401230802437639 PubMed
27. Nelson JC. Effects of baseline depression severity on remission rates with duloxetine and placebo in anxious and nonanxious patients with major depression. J Clin Psychopharmacol. 2011;31(5):682-684. doi:10.1097/JCP.0b013e31822bee26 PubMed
28. Akkaya C, Sivrioglu EY, Akgoz S, et al. Comparison of efficacy and tolerability of reboxetine and venlafaxine XR in major depression and major depression with anxiety features: an open label study. Hum Psychopharmacol. 2006;21(5):337-345. doi:10.1002/hup.770 PubMed
29. Papakostas GI, Stahl SM, Krishen A, et al. Efficacy of bupropion and the selective serotonin reuptake inhibitors in the treatment of major depressive disorder with high levels of anxiety (anxious depression): a pooled analysis of 10 studies. J Clin Psychiatry. 2008;69(8):1287-1292. doi:10.4088/JCP.v69n0812 PubMed
30. Davidson JR, Meoni P, Haudiquet V, et al. Achieving remission with venlafaxine and fluoxetine in major depression: its relationship to anxiety symptoms. Depress Anxiety. 2002;16(1):4-13. doi:10.1002/da.10045 PubMed
31. Sir A, D'Souza RF, Uguz S, et al. Randomized trial of sertraline versus venlafaxine XR in major depression: efficacy and discontinuation symptoms. J Clin Psychiatry. 2005;66(10):1312-1320. doi:10.4088/JCP.v66n1015 PubMed
32. Papakostas GI, Larsen K. Testing anxious depression as a predictor and moderator of symptom improvement in major depressive disorder during treatment with escitalopram. Eur Arch Psychiatry Clin Neurosci. 2011;261(3):147-156. doi:10.1007/s00406-010-0149-3 PubMed
33. Marchesi C, Ceccherininelli A, Rossi A, et al. Is anxious-agitated major depression responsive to fluoxetine? a double-blind comparison with amitriptyline. Pharmacopsychiatry. 1998;31(6):216-221. doi:10.1055/s-2007-979331 PubMed
34. Versiani M, Ontiveros A, Mazzotti G, et al. Fluoxetine versus amitriptyline in the treatment of major depression with associated anxiety (anxious depression): a double-blind comparison. Int Clin Psychopharmacol. 1999;14(6):321-327. doi:10.1097/00004850-199911000-00001 PubMed
35. Uher R, Dernovsek MZ, Mors O, et al. Melancholic, atypical and anxious depression subtypes and outcome of treatment with escitalopram and nortriptyline. J Affect Disord. 2011;132(1-2):112-120. doi:10.1016/j.jad.2011.02.014 PubMed
36. Lenze EJ, Mulsant BH, Dew MA, et al. Good treatment outcomes in late-life depression with comorbid anxiety. J Affect Disord. 2003;77(3):247-254. doi:10.1016/S0165-0327(02)00177-5 PubMed
37. Trivedi MH, Thase ME, Fava M, et al. Adjunctive aripiprazole in major depressive disorder: analysis of efficacy and safety in patients with anxious and atypical features. J Clin Psychiatry. 2008;69(12):1928-1936. doi:10.4088/JCP.v69n1211 PubMed
38. Thase ME, Demyttenaere K, Earley WR, et al. Extended release quetiapine fumarate in major depressive disorder: analysis in patients with anxious depression. Depress Anxiety. 2012;29(7):574-586. doi:10.1002/da.21970 PubMed
39. Farabaugh A, Alpert J, Wisniewski SR, et al. Cognitive therapy for anxious depression in STAR(*) D: what have we learned? J Affect Disord. 2012;142(1-3):213-218. doi:10.1016/j.jad.2012.04.029 PubMed
40. Wu Z, Chen J, Yuan C, et al. Difference in remission in a Chinese population with anxious versus nonanxious treatment-resistant depression: a report of OPERATION study. J Affect Disord. 2013;150(3):834-839. doi:10.1016/j.jad.2013.03.012 PubMed
41. Wiethoff K, Bauer M, Baghai TC, et al. Prevalence and treatment outcome in anxious versus nonanxious depression: results from the German Algorithm Project. J Clin Psychiatry. 2010;71(8):1047-1054. doi:10.4088/JCP.09m05650blu PubMed
42. Chan HN, Rush AJ, Nierenberg AA, et al. Correlates and outcomes of depressed outpatients with greater and fewer anxious symptoms: a CO-MED report. Int J Neuropsychopharmacol. 2012;15(10):1387-1399. doi:10.1017/S1461145711001660 PubMed
43. Delini-Stula A, Mikkelsen H, Angst J. Therapeutic efficacy of antidepressants in agitated anxious depression: a meta-analysis of moclobemide studies. J Affect Disord. 1995;35(1-2):21-30. doi:10.1016/0165-0327(95)00034-K PubMed
44. Flint AJ, Rifat SL. Anxious depression in elderly patients: response to antidepressant treatment. Am J Geriatr Psychiatry. 1997;5(2):107-115. PubMed
45. Flint AJ, Rifat SL. Two-year outcome of elderly patients with anxious depression. Psychiatry Res. 1997;66(1):23-31. doi:10.1016/S0165-1781(96)02964-2 PubMed
46. Baffa A, Hohoff C, Baune BT, et al. Norepinephrine and serotonin transporter genes: impact on treatment response in depression. Neuropsychobiology. 2010;62(2):121-131. doi:10.1159/000317285 PubMed
47. Domschke K, Dannlowski U, Hohoff C, et al. Neuropeptide Y (NPY) gene: impact on emotional processing and treatment response in anxious depression. Eur Neuropsychopharmacol. 2010;20(5):301-309. doi:10.1016/j.euroneuro.2009.09.006 PubMed
48. Binder EB, Owens MJ, Liu W, et al. Association of polymorphisms in genes regulating the corticotropin-releasing factor system with antidepressant treatment response. Arch Gen Psychiatry. 2010;67(4):369-379. doi:10.1001/archgenpsychiatry.2010.18 PubMed
49. Domschke K, Lawford B, Laje G, et al. Brain-derived neurotrophic factor (BDNF) gene: no major impact on antidepressant treatment response. Int J Neuropsychopharmacol. 2010;13(1):93-101. doi:10.1017/S1461145709000030 PubMed
50. Ionescu DF, Niciu MJ, Mathews DC, et al. Neurobiology of anxious depression: a review. Depress Anxiety. 2013;30(4):374-385. doi:10.1002/da.22095 PubMed
51. Drevets WC, Zarate CA Jr, Furey ML. Antidepressant effects of the muscarinic cholinergic receptor antagonist scopolamine: a review. Biol Psychiatry. 2013;73(12):1156-1163. doi:10.1016/j.biopsych.2012.09.031 PubMed
52. Aan Het Rot M, Zarate CA Jr, Charney DS, et al. Ketamine for depression: where do we go from here? Biol Psychiatry. 2012;72(7):537-547. doi:10.1016/j.biopsych.2012.05.003 PubMed